Estrogen receptor (ER) in human breast cancer tissues was demonstrated in paraffin sections as well as in frozen sections by immunoperoxidase methods using monoclonal antibody (H222) against ER. The avidin-biotin-peroxidase complex method was used for the paraffin sections fixed in cold buffered formalin, and the peroxidase-antiperoxidase method was used for the fixed frozen sections. The results were compared with the ER content in the respective tumor tissue determined by dextran-coated charcoal assay. The specific staining for ER was located exclusively in the nuclei of cancer cells in both paraffin and frozen sections. Differences in the intensity and distribution of nuclear staining within a section were often observed, suggesting heterogeneity of the ER content of individual breast cancer cells. In 24 breast cancer tissues studied simultaneously by both paraffin and frozen section methods, 21 (88%) showed similar evaluation of the presence of ER. (6) .
It is generally established that human breast cancer, which is rich in estrogen receptor (ER), responds well to endocrine therapy (1) and that patients with ER-positive breast cancer have a more favorable clinical course and prognosis than those with ER-negative cancer (2) (3) (4) (5) . Therefore, determination of the ER content ofbreast cancer tissue is indispensable for selecting a regimen of treatment when there is a relapse or for predicting the prognosis. The methods of biochemical ER assay, however, are complicated and require radioactive materials. In addition, because of recent progress in diagnosing a smaller lesion, it is often impossible to obtain enough tissue (0.5 g or more) needed for the conventional radioligand assay. Furthermore, the biochemical ER assay cannot evaluate heterogeneity of ER content among the breast cancer cells, which could be a reason for the unresponsiveness to endocrine therapy of about 40% of patients with ER-positive breast cancer (6) .
In order to circumvent these disadvantages of the current ER assay, many immunocytochemical methods using antiestradiol antibody (7) (8) (9) (10) (11) and cytochemical methods using fluorescein-or peroxidase-labeled estradiol (12) (13) (14) (15) have been proposed. However, sucrose gradient analysis revealed that the antibodies against estradiol do not necessarily detect the estradiol-ER complex (16) . In addition, affinity of the estradiol-conjugate for ER was shown to be extremely low when compared with that of free estradiol (17) (18) (19) . Although these published methods were aimed at visualizing the specific binding of estrogen to ER, the methods of tissue preparation used in these studies could not prevent the loss of ER through diffusion or the reduced ability of estrogen to bind to its receptor (20) . Therefore, it is reasonable to conclude that the stains obtained by these immunocytochemical and cytochemical methods are not specific for ER (16) (17) (18) (19) (20) .
Recently, monoclonal antibodies to human ER were developed by Greene et al. (21) and Miller et al. (22) . By use of these monoclonal antibodies against ER, King and Greene first demonstrated ER in frozen tissue sections prepared from human breast cancer and other sources (23) . These monoclonal antibodies are highly specific for ER and could serve as a more reliable probe for detecting ER in tissues. However, frozen sections have limitations in their use for detailed examination of tumor morphology and for retrospective studies.
In this study, methods were developed to demonstrate ER in cold formalin-fixed paraffin sections as well as in frozen sections of human breast cancer tissues by use ofone of these monoclonal antibodies. The utility of immunocytochemical staining of ER was evaluated by comparing the results with the results of determining ER content by the dextran-coated charcoal (DCC) assay. (Fig. 2) . The ER-specific immunostaining covered the nucleus of the positive cell diffusely, but the intensity of the nuclear staining was not always uniform (Fig. lA) . Frequently, the distribution of positive nuclear staining varied considerably, depending on the area within a section (Fig. 3) . The heterogeneity of the nuclear staining in distribution and intensity did not correspond to differences in tumor histology. However, the tumor cells with prominent nuclear atypia, or pleomorphism tended to be negative for ER by immunocytochemistry.
MATERIALS AND METHODS
Although no cytoplasmic staining was observed in the frozen sections, it was seen in a few paraffin sections. However, it was very faint when compared with the nuclear staining, and similar faint cytoplasmic staining was also seen in slides of paraffin sections incubated with normal rat IgG (control). Moreover, no nuclear staining was observed in the negative controls of either paraffin (Fig. 1B) unlikely that these false negatives would have been positive by immunostaining of frozen sections since there was such excellent correlation of the immunostaining results when both paraffin and frozen sections were examined in the same tumor (Table 1 ). In contrast, there were 7 positive tumors by immunostaining of paraffin sections that were negative by the DCC assay. These examples of "false positive" and "false negative" results will require evaluation of patient outcomes and the results of endocrine therapy to establish the relative value of immunostaining versus the DCC assay as a useful marker in the treatment of breast cancer. Certainly, the use of immunostaining offers the opportunity to study simultaneously the histology and presence of ER. This may be very useful when a tumor is so small as to preclude both histological and biochemical examination. While the tissue preparation and the staining procedures for the paraffin sections require more time than for the frozen sections, there are several advantages in the immunocytochemical demonstration of ER in the paraffin sections. The histopathological structures of the paraffin sections are conserved in a better condition, making it possible to examine the histological characteristics of the tumor in more detail. In addition, the paraffin-embedded tumor tissues fixed in cold formalin can be stored for a longer time and used for restaining. Therefore, the paraffin sections described in this paper may be more suitable for laboratory and clinical research on ER in human breast cancer. It should be noted that the fixation in cold formalin used in this study differs from the conventional method of fixation utilized in most clinical laboratories. Such conventional fixation did not produce reliable and reproducible results. Preliminarily, we tried both the PAP and ABC method in both paraffin and frozen sections. At the same concentration of H222, the sensitivity of the ABC method was superior to that of the PAP method in paraffin sections. However, because the background staining in the ABC method, which might be due to the endogenous biotin, was considerably stronger than that in the PAP method, the PAP method was employed in frozen sections.
King and Greene (23) reported that the immunocytochemical staining specific for ER was confined to the nuclei of human breast cancer, MCF-7 cells, and rabbit uterus, when frozen sections were examined. Our results also show that ER staining is confined to the nuclei in both paraffin and frozen sections.
For a number of years it has been accepted that the ER is located in the cytosol and translocates to the nucleus after estrogen binding and activation (35) . The monoclonal antibody against ER used in this study has already been shown to bind to the cytoplasmic as well as to the nuclear form of ER (22) . Accordingly, the specific staining of ER would be expected to be observed in both the cytoplasm and nucleus of an ER-containing cell. Therefore, it is not clear why there is the absence of cytoplasmic staining in ER-positive cells. One possibility is that the tissue fixation and/or staining procedures results in the loss of the cytoplasmic form of ER because of either translocation into the nucleus or some other type of artifact produced by these processes. It has been reported that when unfixed frozen sections are used, considerable amounts of ER are released into the supernatant (20) . However, in the case of paraffin sections, the cytosolic ER may not be as easily washed out because the tumor tissues are already fixed in buffered formalin.
An alternative possibility, proposed recently by King and Greene (23) , is that ER might be present exclusively in the nuclei of ER-positive cells. There are several reports that support this concept and suggest that the cytoplasmic form of ER represents ER released from the nucleus during extraction (36, 37) . This is an interesting interpretation, but further studies are needed to conclude that ER is present only in the nucleus.
It has been reported that the ER content varies from site to site even in the same breast cancer (38, 39) . Similarly, in the present study we often noticed that ER-positive tumors showed patchwork or mosaic staining patterns, and that the intensity of the nuclear staining of ER-positive cells varied from cell to cell. These findings may be one of the reasons for the discrepancy between the results of the immunocytochemical staining and those of the DCC assay. Therefore, when a tumor is large, it would be of interest to compare the results of the ER-immunostaining of multiple portions from the same tumor with that of the DCC assay.
The immunocytochemical assay is the most suitable method for examining the heterogeneity of ER in breast cancers. The heterogeneity of the ER stain may be attributable to the mosaic of cells with different ER contents, the phase of the cell cycle, and/or the heterogeneity ofthe ER molecule itself. A detailed study on ER heterogeneity may provide additional information regarding the clinical unresponsiveness seen in about 40% of patients with ER-positive breast cancer.
